Alligator Bioscience
Søren Bregenholt – born 1971, Chief Executive Officer – holds a Ph.D. in biomedical research from the University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen, and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration, and co-development agreements. Employed since June 2021 and member of the Management Team since 2021.
This person is not in any offices
Alligator Bioscience
1 followers
Alligator Bioscience utvecklar antikroppsbaserade läkemedel för behandling av cancer. Bolaget är specialiserat på utveckling av tumörriktad immunterapier.